Everolimus after surgery can improve outcomes in those with high-risk kidney can...
Dr Christopher Ryan - OHSU Knight Cancer Institute, Portland, USA
Everolimus after surgery can improve outcomes in those with high-risk kidney cancer ( Dr Christopher Ryan - OHSU Knight Cancer Institute, Portland, USA )
4 Jun 2022
Advance Prostate Cancer Consensus Conference 2021: Report
Prof Silke Gillessen and Prof Aurelius Omlin
Advance Prostate Cancer Consensus Conference 2021: Report ( Prof Silke Gillessen and Prof Aurelius Omlin )
29 Apr 2022
ASCO GU 2022: Prostate roundup
Prof Eleni Efstathiou, Prof Axel Merseburger and Dr Neal Shore
ASCO GU 2022: Prostate roundup ( Prof Eleni Efstathiou, Prof Axel Merseburger and Dr Neal Shore )
20 Apr 2022
Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid ...
Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia
Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid tumours ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia )
14 Apr 2022
PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/...
Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA
PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )
13 Apr 2022
ASCO GU 2022: Latest in mHSPC
Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith
ASCO GU 2022: Latest in mHSPC ( Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith )
8 Mar 2022
ASCO GU 2022: PARP inhibitors in prostate and MAGNITUDE
Dr Neal Shore and Prof Kim Chi
ASCO GU 2022: PARP inhibitors in prostate and MAGNITUDE ( Dr Neal Shore and Prof Kim Chi )
4 Mar 2022
An AI-derived digital pathology-based biomarker to predict the benefit of ADT in...
Prof Daniel Spratt - University Hospitals Seidman Cancer Center, Cleveland, USA
An AI-derived digital pathology-based biomarker to predict the benefit of ADT in PC with validation in NRG/RTOG 9408 ( Prof Daniel Spratt - University Hospitals Seidman Cancer Center, Cleveland, USA )
3 Mar 2022
SG in combination with pembro in patients with mUC who progressed after platinum...
Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA
SG in combination with pembro in patients with mUC who progressed after platinum (PLT)-based regimens ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )
28 Feb 2022
NMIBC treated with IL-15RαFc superagonist N-803 and BCG infusion
Prof Sam Chang - Vanderbilt University School of Medicine, Nashville, USA
NMIBC treated with IL-15RαFc superagonist N-803 and BCG infusion ( Prof Sam Chang - Vanderbilt University School of Medicine, Nashville, USA )
28 Feb 2022
Latest developments in mHSPC
Prof Kurt Miller and Prof Laura-Maria Krabbe
Latest developments in mHSPC ( Prof Kurt Miller and Prof Laura-Maria Krabbe )
25 Feb 2022
Evaluating a polygenic hazard score to predict risk of developing metastatic or ...
Dr Meghana Pagadala - University of California San Diego, San Diego, USA
Evaluating a polygenic hazard score to predict risk of developing metastatic or fatal prostate cancer ( Dr Meghana Pagadala - University of California San Diego, San Diego, USA )
25 Feb 2022